Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Gelatin sales increased, supported by firm demand in North America, although sales of pharmaceutical-grade products in Japan declined and selling prices in India fell. Collagen peptide benefited from demand for protein products in North America and firm demand in the Indian and Asian markets. New adoption in customers' products drove higher sales of food ingredients, while growth in overseas sales drove higher biomedical sales. In addition, some sales of cosmetic ingredients were reclassified from collagen peptides to biomedical products, and the figures for the previous corresponding period are presented using the revised classification for comparison.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥9,893 million (YoY +8.3%) |
| Operating profit | ¥1,184 million (YoY -5.5%) |
| Ordinary income | ¥1,271 million (YoY +1.8%) |
| Profit attributable to owners of the parent | ¥690 million (YoY +10.4%) |
| Net income per share | ¥37.93 |
| Equity ratio | End of the current fiscal period 57 / End of previous period 56.6 |
| Total assets | ¥44,096 million |
| Net assets | ¥30,849 million |
| Full-year earnings forecast | Net Sales ¥43,000 million (YoY +13.0%) / Operating profit ¥4,700 million (YoY +0.8%) / Ordinary income ¥4,800 million (YoY +0.3%) / Net income ¥2,400 million (YoY -26.9%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥30 → ¥40（+33.3%） |
| Depreciation and amortization | ¥323 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of non-current assets / Amount ¥6 million, Item Gain on sale of investment securities / Amount ¥35 million / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥0 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Added: 0 companies; excluded: 0 companies |
| Material subsequent events | On 7 August 2026, 15,600 treasury shares were disposed of for a total of ¥20,794,800 as restricted stock compensation. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No (no eligible attendees) |
| Issued Shares at Period-End | 18,373,974 |
| Treasury Shares at Period-End | 160,888 |
| Factors Behind Changes in Business Performance | Gelatin sales increased, supported by firm demand in North America, although sales of pharmaceutical-grade products in Japan declined and selling prices in India fell. Collagen peptide benefited from demand for protein products in North America and firm demand in the Indian and Asian markets. New adoption in customers' products drove higher sales of food ingredients, while growth in overseas sales drove higher biomedical sales. In addition, some sales of cosmetic ingredients were reclassified from collagen peptides to biomedical products, and the figures for the previous corresponding period are presented using the revised classification for comparison. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in net sales was attributed to expanding demand in North America, demand for collagen peptides for protein products, new adoption in food ingredients, and growth in overseas sales of biomedical products. No direct reason was provided for the decline in operating profit.